Blog

27 Jun

SEC FIlings

Registration of securities, business combinations – Amendment

November 17, 2022
Posted by Jitendra

16 Jun

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

14 Jun

Press Release

Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.

June 28, 2022
Posted by Jitendra

Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults.Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States1. As gout cases increase...

07 Jun

SEC FIlings

Notice of Annual Meeting

November 17, 2022
Posted by Jitendra

03 Jun

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

03 Jun

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

03 Jun

Press Release

Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes

June 2, 2022
Posted by Jitendra

PALO ALTO and SAN DIEGO, CA. June 3, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial...

02 Jun

Press Release

Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido^® in managed health care plans

June 2, 2022
Posted by Jitendra

Earlier this year, a national pharmacy benefit manager (PBM) moved a large percentage of its patients from not covered to covered, adding access to ZTlido for 5.5 million lives. ZTlido is now...

27 May

SEC FIlings